Study of Trypanosoma brucei Pteridine Reductase and Its Inhibition by Methotrexate
Author Information
Author(s): Dawson Alice, Gibellini Federica, Sienkiewicz Natasha, Tulloch Lindsay B, Fyfe Paul K, McLuskey Karen, Fairlamb Alan H, Hunter William N
Primary Institution: University of Dundee
Hypothesis
The study aims to characterize the structure and reactivity of Trypanosoma brucei pteridine reductase (TbPTR1) and its inhibition by methotrexate.
Conclusion
The study reveals that TbPTR1 has distinct structural features that could be targeted for developing new inhibitors against African trypanosomiasis.
Supporting Evidence
- TbPTR1 is more active than LmPTR1 with respect to reduction of pterins.
- The crystal structure of TbPTR1 was determined at 2.2 Å resolution.
- TbPTR1 displays substrate inhibition with DHB as a variable substrate.
- The study suggests that targeting both PTR1 and DHFR could improve treatment for trypanosomatid infections.
Takeaway
Researchers looked at a protein in a parasite that helps it grow and found out how a common drug can stop it from working.
Methodology
The study involved cloning the TbPTR1 gene, producing the recombinant protein in E. coli, and determining its crystal structure in complex with NADP+ and methotrexate.
Limitations
The presence of modifications in the active site due to the crystallization process may affect the kinetic characterization of the enzyme.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website